Sumitomo Pharma
4506 · TSE
Public Market Listing
Live quotes, historical charts, and market capitalization for Sumitomo Pharma are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(7 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | norepinephrine precursorSmall molecule | Parkinson's DiseaseNeurogenic Orthostatic Hypotension | |
Eslicarbazepine acetate(Aptiom) | Approved | Voltage-gated sodium channelSmall molecule | Epilepsy Focal Onset Seizures |
| Approved | Dopamine D2/D3 receptor + 5-HT7 receptor · Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | SchizophreniaBipolar Depression | |
Vildagliptin(Galvus) | Phase 3 | DPP-4Small molecule | Type 2 Diabetes |
| Phase 1/2 | Menin-KMT2A protein-protein interactionSmall molecule | Acute Myeloid Leukemia | |
| Phase 1/2 | Allogeneic iPSC-derived dopaminergic progenitor cellsCell therapy | Parkinson's Disease | |
| Phase 1/2 | Checkpoint kinase 1 (CHK1)Small molecule | Non-Small Cell Lung Cancer |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
2028 (1)
2030 (1)
December 2030 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $3.0B | $289M | — | — | report ↗ |